10th Nov 2026 07:48
RUA Life Sciences PLC - holding company of multiple medical device businesses - Expects to report pretax profit of GBP4.7 million for the 12 months ended September 30. Revenue is expected to rise by 7.8% to GBP5.5 million from GBP5.1 million in the final 12 months of the previous 18-month reporting period. Says its contract development and manufacturing operations generate GBP2.8 million in revenue, while medical device company Abiss records revenue of GBP1.4 million, below its GBP1.9 million target, due to inventory reductions at a major customer. RUA Life expects to report adjusted earnings before interest, tax, depreciation and amortisation of around GBP300,000. Says it continues to evolve and makes good progress in developing its core business. Expects to publish its financial 2026 results towards the end of January.
Current stock price: 23.39 pence, down 8.3% in London on Monday.
12-month change: up 80%
By Niall Holden, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Rua Life Sci.